Appclon Registers Domestic Patent for Bispecific Antibody 'AM105'... Begins Primate Testing

Patent Registered for CD137-Binding Affibody Sequence; Applications Filed in Seven Countries Including the US and Europe
Toxicity Testing Initiated at Partner's Request; Pursuing Global Technology Transfer

Appclon announced on August 14 that it has completed domestic patent registration for a core technology applied to its next-generation bispecific antibody cancer immunotherapy, "AM105."

Appclon company logo image. Appclon

Previously, AM105-related patents were filed in seven countries and regions, including the United States, Europe, China, Japan, India, Russia, and Brazil. The latest patent concerns the Affibody sequence that specifically binds to the extracellular domain of the receptor "CD137," which is responsible for activating the immune response of T cells. The patent covers the amino acid sequences of eight CD137-binding Affibody variants, as well as related protein complexes and anti-cancer compositions, thereby defining the scope of their proprietary rights.

AM105 is a pipeline candidate developed using Appclon's bispecific antibody platform "AffiMab." It targets both EGFR, a major tumor marker in colorectal and lung cancer, and CD137, which is involved in T cell activation.

AM105 binds to cancer cells via EGFR and then activates CD137, thereby triggering an anti-cancer immune response at the tumor site. The company aims to focus immune activation at tumor sites through this approach, reducing side effects associated with systemic immune activation.

Appclon explained that, in preclinical studies, AM105 demonstrated anticancer potential in situations where conventional EGFR-targeted therapies such as cetuximab and panitumumab were ineffective or where resistance emerged after treatment with EGFR inhibitors such as gefitinib and erlotinib.

Currently, at the request of a partner company showing interest in AM105, Appclon has initiated primate toxicity testing. Based on the results, the company plans to pursue global technology transfer and joint development.

A company representative stated, "With this patent registration, we have secured rights to the CD137-binding Affibody sequence, the core of AffiMab," and added, "Alongside AM105 development, we will also pursue platform expansion to target various tumor markers."

This content was produced with the assistance of AI translation services.